Search

Your search keyword '"Yoon, Dok-Hyun"' showing total 7 results
Start Over Author "Yoon, Dok-Hyun" Journal international journal of hematology
7 results on '"Yoon, Dok-Hyun"'

2. Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia

Author

Lee, Yong-Pyo, Yoon, Sang Eun, Song, Yuqin, Kim, Seok Jin, Yoon, Dok Hyun, Chen, Tsai-Yun, Koh, Young Il, Kang, Ka Won, Lee, Ho sup, Wei, Kevin Tay Kuang, Lim, Soon Thye, Poon, Michelle, Irawan, Cosphiadi, Zhao, Weili, Do, Young Rok, Lee, Mark Hong, Ng, Soo Chin, Lee, Won-Sik, Guo, Ye, Zhang, Huilai, Kang, Hye-Jin, Yun, Hwan Jung, Kim, Hyo Jung, Lung, Daryl Tan Chen, Kwak, Jae-Yong, Han, Jae Joon, Mun, Yeung-Chul, Oh, Sung Yong, Shim, Hyeok, Kwon, Jung Hye, Sohn, Byeong Seok, Park, Seong Kyu, Jo, Jae Cheol, Ko, Young Hyeh, Jun, Zhu, and Kim, Won Seog

Published
2021
Full Text
View/download PDF

7. Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone.

Author

Lee, Ho Sup, Kim, Kihyun, Lee, Je-Jung, Yoon, Sung-Soo, Bang, Soo-Mee, Kim, Jin Seok, Eom, Hyeon-Seok, Yoon, Dok Hyun, Lee, Yoojin, Shin, Ho-Jin, Park, Yong, Jo, Jae-Cheol, Lee, Won Sik, Do, Young Rok, Mun, Yeung-Chul, Lee, Mark Hong, Kim, Hyo Jung, Kim, Sung-Hyun, Kim, Min Kyoung, and Lim, Sung-Nam

Abstract

We compared efficacy and safety, according to frailty, of elderly patients with relapsed and refractory multiple myeloma (RRMM) treated with lenalidomide and dexamethasone (Rd), for whom bortezomib treatment had failed. Patients, 164 (52.9%) and 146 (47.1%), were classified as non-frail and frail using a simplified frailty scale. The overall response rates (ORR) and survival outcomes were lower in frail than in non-frail patients (ORR: 56.2% vs. 67.7%, P = 0.069; median progression free survival: 13.17 vs. 17.80 months, P = 0.033; median overall survival: 23.00 vs. 36.27 months, P = 0.002, respectively). The number of treatment emergent adverse events in grade 3 or worse was higher in frail than in non-frail patients (41.8% vs. 24.4%, P = 0.002, respectively). In frail patients, independent poor prognostic factors for survival were two or more Charlson comorbidity index (CCI) score, prior to exposure to both bortezomib and thalidomide, and achieved less than partial response In conclusion, frailty could predict clinical outcomes of Rd treatment in elderly patients with RRMM who had failed prior bortezomib. In frail patients, lower CCI in addition to less previous treatment exposure and deep response were associated with better survival. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results